OUTCOMES WITH INFLIXIMAB AND ITS BIOSIMILARS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA): REAL-WORLD EXPERIENCE IN THE US

被引：0
|
作者：
Helfgott, S. M. [1 ]
Radtchenko, J. [2 ]
Soloman, N. [3 ]
Huston, K. [4 ]
Singh, J. A. [5 ]
Edgerton, C. [6 ]
机构：
[1] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[2] Trio Hlth, Louisville, CO USA
[3] Arizona Arthrit & Rheumatol Associates, Phoenix, AZ USA
[4] Ctr Rheumat Dis & Allergy Immunol, Kansas City, MO USA
[5] Univ Alabama Birmingham, Birmingham, AL USA
[6] Articularis Healthcare, Summerville, SC USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PBI4
引用
收藏
页码：S14 / S15
页数：2
相关论文
共 50 条
  • [31] SUSTAINABLE LOW DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: REAL-WORLD EXPERIENCE WITH TOCILIZUMAB
    Shivacheva, T.
    Georgiev, T.
    Hristova, S.
    Dimitrov, S.
    Bogdanova-Petrova, S.
    Gerganov, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1138 - 1138
  • [32] Characteristics and Outcomes of Patients with Rheumatoid Arthritis Treated with Upadacitinib in a Global Real-World Setting
    Caporali, Roberto Felice
    Patel, Jayeshkumar
    Howell, Oliver
    Strengholt, Sander
    Jones, Hannah
    Taylor, Peter
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 545 - 548
  • [33] CHARACTERISTICS AND OUTCOMES IN A REAL-WORLD COHORT OF RHEUMATOID ARTHRITIS PATIENTS WITH COVID-19
    Ye, Y.
    Yue, X.
    Krueger, W.
    Wegrzyn, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 860 - 860
  • [34] Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting
    Baker, Joshua F.
    Bakewell, Catherine
    Dikranian, Ara
    Lam, Gordon
    O'Brien, Jacqueline
    Moore, Page C.
    Yu, Miao
    Hur, Peter
    Masri, Karim R.
    RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 841 - 853
  • [35] USE OF REAL-WORLD EVIDENCE TO EVALUATE INFLIXIMAB BIOSIMILARS: A SCOPING REVIEW
    Cheung, A.
    Powell, L. C.
    Rahim, T.
    Emerson, S.
    Johnston, K.
    VALUE IN HEALTH, 2022, 25 (01) : S18 - S19
  • [36] REAL-WORLD EVALUATION OF TNF INHIBITOR UTILISATION IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A US CLAIMS DATABASE
    Harnett, J.
    Wiederkehr, D.
    Gerber, R.
    Gruben, D.
    Koenig, A.
    Bourret, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 229 - 229
  • [37] Corticosteroid use in Rheumatoid Arthritis Patients Taking Infliximab: Treatment Implications Based on a Real-world Canadian Population
    Haraoui, Boulos
    Jovaisas, Algis
    Bensen, William
    Faraawi, Rafat
    Dixit, Sanjay
    Rampakakis, Emmanouil
    Nantel, Francois
    Otawa, Susan
    Lehman, Allen
    Shawi, May
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 961 - 962
  • [38] Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry
    M. Cárdenas
    S. de la Fuente
    P. Font
    M. C. Castro-Villegas
    M. Romero-Gómez
    D. Ruiz-Vílchez
    J. Calvo-Gutiérez
    A. Escudero-Contreras
    M. A. Casado
    J. R. Del Prado
    E. Collantes-Estévez
    Rheumatology International, 2016, 36 : 231 - 241
  • [39] Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population
    Haraoui, Boulos
    Jovaisas, Algis
    Bensen, William G.
    Faraawi, Rafat
    Kelsall, John
    Dixit, Sanjay
    Rodrigues, Jude
    Sheriff, Maqbool
    Rampakakis, Emmanouil
    Sampalis, John S.
    Lehman, Allen J.
    Otawa, Susan
    Nantel, Francois
    Shawi, May
    RMD OPEN, 2015, 1 (01):
  • [40] Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry
    Cardenas, M.
    de la Fuente, S.
    Font, P.
    Castro-Villegas, M. C.
    Romero-Gomez, M.
    Ruiz-Vilchez, D.
    Calvo-Gutierez, J.
    Escudero-Contreras, A.
    Casado, M. A.
    Del Prado, J. R.
    Collantes-Estevez, E.
    RHEUMATOLOGY INTERNATIONAL, 2016, 36 (02) : 231 - 241
12345